Abivax SA American Depositary Shares

Abivax stock surged on market rumors of a potential takeover by Eli Lilly, following impressive clinical trial results for its ulcerative colitis treatment obefazimod.

Abivax reported positive Phase 3 trial results for obefazimod in treating ulcerative colitis, with a 16.4% placebo-adjusted clinical remission rate at Week 8 and no significant safety concerns.

The article explores two promising biotech companies, Viking Therapeutics and Recursion Pharmaceuticals, highlighting their innovative approaches in weight loss treatments and AI-driven drug development, respectively.

French biotechnology company Abivax SA reported positive Phase 3 clinical trial results for obefazimod, a treatment for ulcerative colitis, causing its stock to surge over 400% in premarket trading on July 23, 2025.

Stay informed of upcoming market events with Seeking Alpha's Stocks to Watch.